Joint Commercialization Strategy with Hans Biomed
Synergy Expected with Botulinum Toxin and Hyaluronic Acid (HA) Fillers

Hugel has secured the official domestic distribution rights for the extracellular matrix (ECM)-based product 'CellREDM™', marking a step forward in expanding its aesthetics portfolio.


At the 'Cellrdm Business Agreement Signing Ceremony' held at Hugel Seoul Office, Jang Doohyun, CEO of Hugel (right), and Kim Geunyoung, CEO of Hans Biomed, are taking a commemorative photo. Hugel.

At the 'Cellrdm Business Agreement Signing Ceremony' held at Hugel Seoul Office, Jang Doohyun, CEO of Hugel (right), and Kim Geunyoung, CEO of Hans Biomed, are taking a commemorative photo. Hugel.

View original image

On April 1, Hugel announced that it had signed a domestic distribution agreement for CellREDM with Hans Biomed. Hans Biomed is the first company in Asia to be accredited by the American Association of Tissue Banks (AATB), which is the world’s most prestigious tissue bank standards organization, evaluating quality stability and ethical standards.


CellREDM is developed using human acellular dermal matrix (hADM), a human tissue-derived material, and directly supplements extracellular matrix components such as collagen and elastin to help restore skin structure. As a result, Hugel is now able to offer a more comprehensive solution in the aesthetics field, extending beyond wrinkle and volume enhancement to include skin regeneration.


This agreement is significant in that Hugel, which has previously focused on products developed in-house, is now expanding its portfolio through strategic collaboration with external partners. In particular, ECM is actively used in combination with hyaluronic acid (HA) products and various procedures, and is expected to create synergies with Hugel’s mainstay products, such as botulinum toxin and hyaluronic acid (HA) fillers.


The two companies plan to enhance distribution efficiency and facilitate rapid market entry by implementing joint promotions and commercialization strategies tailored to the characteristics and expertise of specialized hospitals and clinics.


Geunyoung Kim, CEO of Hans Biomed, stated, “Based on our partnership with Hugel, we will promote the quality excellence of CellREDM—which reduces downtime and pain after procedures through Hans Biomed’s proprietary tissue processing technology as Korea’s first tissue bank—and seek to maximize growth.”



Doohyun Jang, CEO of Hugel, said, “We plan to further solidify our leading position in the industry by swiftly responding to potential demand in the medical aesthetics market. We will use this agreement as a starting point for Hugel’s business expansion and continue to explore new business opportunities both domestically and internationally.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing